Sex differences in therapeutic outcomes of recombinant human brain natriuretic peptide in patients with coronary artery disease combined with acute heart failure

Zhi-jun WU,Feng-ru ZHANG,Wei JIN,Yan LIU
DOI: https://doi.org/10.3969/j.issn.1673-6583.2013.06.021
2013-01-01
Abstract:Objective:To explore the gender-related differences of clinical curative effect and safety of recombinant human brain natriuretic peptide(rhBNP)in patients with coronary artery disease(CAD) combined with acute heart failure. Methods:A total of 67 CAD patients with acute heart failure were selected,including 33 men and 34 women.All patients were given rhBNP on the basis of standard antiheart failure therapy.Clinical symptoms,24-hour urinary output,serum NT-proBNP levels,other biochemical indexes and adverse drug effects were examined before and after rhBNP treatment.The major adverse cardiac events(MACE)were also observed up to 1 month after drug infusion. Results: Compared to the baseline levels,24-hour urinary output significantly increased in both groups(P= 0.002)and the reduction of NT-proBNP was statistically significant in women group(P=0.003)after rhBNP infusion.However,the between-group variation of 24-hour urinary output and NT-proBNP showed no significant differences.The total effective rate in men was significantly higher than that in women(P=0.033),but the adverse drug effects and MACE were similar. Conclusion:RhBNP significantly and safely improves clinical symptoms of CAD patients with acute heart failure,and the efficiency in men is higher than that in women.
What problem does this paper attempt to address?